News

Stem Cell Guru: Episode 3

LAUNCH of the STEMY COIN – stem cell technology backed coin

LA TOKEN has just announced what could be arguably the most appealing Initial Exchange Offering in the past decade.

It features a stem cell technology backed coin named “Stemy Coin” that is seeking FDA approval for COVID 19 stem cell treatment solutions based not only on the immunomodulatory and anti-inflammatory capacity of stem cells, but also regeneration and reconstruction of damaged tissues.

BHI and Stem Cell Biotech have successfully treated 34 coronavirus patients in Wuhan. This Stem Cell technology has also been proven to effectively address cancer, strokes, heart attacks, diabetes, kidney, liver, and lung disease. GDIH First Response and Stem Cell Biotech will be rolling out 100 clinics around the world, in partnership BHI to combat Covid-19 worldwide. This could be the fastest rising digital currency in the blockchain industry.

Brian Mehling, M.D., M.S. , the founder and chief medical officer of Blue Horizon International, who is also a board certified orthopedic surgeon, made the news!

Brian Mehling, M.D. – the Founder and Chief Medical Officer of Blue Horizon International (BHI), answers questions on Stem Cells in Regenerative Medicine (Episode 2)

Brian Mehling, M.D. – the Founder and Chief Medical Officer of Blue Horizon International (BHI), answers questions on Stem Cells in Regenerative Medicine

Happy Nurses Week

HAPPY NURSES WEEK!

The theme for National Nurses Week in 2020 is Compassion|Expertise|Trust.

National Nurses Week is celebrated annually from May 6, also known as National Nurses Day, through May 12, the birthday of Florence Nightingale, the founder of modern nursing. This week is devoted to highlighting the diverse ways in which registered nurses work to improve health care.

We have never been able to repay nurses for all the work they do. For how thankful we’ll always be, nothing can repay the sacrifices they make in supporting doctors, consoling families, and being friends to patients. They make doctor visits and hospital stays a little more compassionate. This is all in addition to their actual jobs, which require tremendous skill and years of education, all of which have been put to the ultimate test in light of the novel coronavirus pandemic.

Blue Horizon Charitable Foundation is seeking funding to help fight COVID-19

What if stem cell treatments could help those with COVID-19?

What if pneumonia brought on by the virus could be cured?

That’s what we here at Blue Horizon are trying to find out.  Our previous studies have shown that mesenchymal stem cells  from the human umbilical cord have immunomodulatory,  antimicrobial, anti-inflammatory and tissue repair functions, being a great potential for the prevention and treatment of viral diseases.

Presently we are in the process of submission and obtaining an endorsement from the Food and Drug Administration (FDA) to initiate the clinical trial of the human umbilical cord-derived stem cell  administration in patients with severe COVID-19 pneumonia.

Application of the high-quality clinical-grade stem cell source is critical for the successful development and conduct of our study. We are seeking funding to incorporate high-quality stem cells in our study and initiate FDA endorsed clinical trials.

For more information, please visit www.bluehorizonfoundation.org or email us at info@bluehorizonfoundation.org

Chinese doctor claims he made a breakthrough in coronavirus pandemic with stem cell injections – having 100% success rate after treating nine mostly elderly patients

Click below to read the original article:

https://www.dailymail.co.uk/news/article-8116881/Doctor-claims-breakthrough-stem-cell-injections-treat-coronavirus.html?fbclid=IwAR07-IKhsVH7gE4rWfRC5CdmDlQvqCxfvJmHmmhceogeqwH_cdGwMRxHDDg

Dr. Wu Summary On Coronavirus Study

Brief Summary:

The 2019 novel coronavirus pneumonia first emerged in Wuhan, Hubei, China, in December 2019. The disease spread quickly to 26 countries worldwide representing a serious global public health threat. Common signs of infection include respiratory symptoms, fever, dry cough, shortness of breath and breathing difficulties. In more severe cases, the infection can cause pneumonia, severe acute respiratory system injury with overwhelming inflammation in the lung. To date, there are no anti-viral therapeutics that specifically target human coronaviruses, so treatments are only supportive. The present clinical trial is aimed to evaluate the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for the therapy of novel coronavirus pneumonia patients.

Detailed description:

In late December 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).

The virus that causes COVID-19 is infecting people and highly contagious, spreading easily from person-to-person. The number of infected cases is growing in China and worldwide. As of February 20, a total of 54,959 confirmed cases were reported in China. To date, there is no effective treatment for patients affected with novel coronavirus pneumonia, and new therapeutic methods for the treatment of patients are urgently needed.
A recent study regarding the 2019 novel coronavirus pneumonia, published in The Lancet and The New England Journal of Medicine, discovered the massive inflammatory cell infiltration and inflammatory cytokines secretion in patients’ lungs, alveolar epithelial cells, causing damage of capillary endothelial cells and acute lung injury. Based on this discovery, it seems that the key to cure pneumonia is to inhibit the inflammatory response. This will reduce the damage of alveolar epithelial cells and endothelial cells and repair the function of the lung.

Mesenchymal stem cells (MSCs) are extensively used in basic research and clinical application. Research shows that these cells can migrate to damaged tissues, exert anti-inflammatory and immunoregulatory functions, promote the regeneration of damaged tissues and inhibit tissue fibrosis. Studies are showing that MSCs can significantly reduce H9N2 and H5N1 viruses induced acute lung injury in mice model by bringing down the level of proinflammatory cytokines and mobilizing the inflammatory cells in the lungs.

Compared to MSCs from other sources, human umbilical cord-derived MSCs (UC-MSCs) have been commonly used in clinical studies due to their convenient collection, lack of ethical concerns, low immunogenicity, and rapid proliferation rate. In our recent research studies, we confirmed that UC-MSCs can significantly reduce inflammatory cell infiltration and inflammatory factors expression in lung tissue, significantly protecting lung tissue from endotoxin (LPS) -induced acute lung injury in mice.

The purpose of this clinical study is to evaluate the safety and efficiency of UC-MSCs in the therapy of pneumonia patients infected by 2019-nCoV. We are planning to recruit 48 participants aged from 18 to 75 years old with no severe underlying diseases. In the experimental group, 24 participants will receive intravenous administration of 0.5*106 UC-MSCs/kg body weight (4 administrations every other day in conjunction with conventional therapy). In the control group, the other 24 participants will receive conventional treatment plus 4 times of placebo intravenously. The lung CT, blood biochemical examination, lymphocyte subsets, inflammatory factors, 28-days mortality, etc. will be evaluated within 24h and 1, 2, 4, 8 weeks after UC-MSCs treatment.

Brian Mehling, MD participates in 9th Annual Brain Mapping Day

Brian Mehling, MD participated in the 9th Annual Brain Mapping Day: A joint Congressional briefing with the Society for Brain Mapping and Therapeutics, Brain Mapping Foundation, and the Congressional Neuroscience Caucus yesterday in Washington DC. The topic of Dr. Mehling’s presentation was “Safety and Efficacy of Stem Cell Therapy in Clinical Applications.” The materials presented focused on educating lawmakers about new technologies and innovations in the field of neuroscience, including stem cell therapy, enabling policies that are aligned with advancements made in science and technology. Millions of Americans are impacted by neuro-psychiatric, neurological disorders, and spinal disorders, creating a great need for proper regulation.

BHI Therapeutic Sciences Jamaica celebrates one year anniversary 

A little more than one year ago, BHI Therapeutic Sciences Jamaica (BHI Jamaica), located in Montego Bay opened its doors and welcomed its first stem cell therapy patients. Since then, more than 50 patients have been treated with advanced stem cell therapies. 

 Brian Mehling, MD said: “Cellular medicine is in high demand and stem cells have the potential to treat a wide range of diseases. Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. In addition, stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue.”

BHI Therapeutic Sciences Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety. BHI Therapeutic Sciences Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedic conditions.

Lance Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training. Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic.

“My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and provides an increase in overall energy. I’ve seen more improvement  in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.”

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety. We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board- certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedics conditions. 

For more information please visit www.bhijamaica.com

 Brian Mehling, MD, (R) and Dongecheng Wu, MD, Ph.D., (L) during the stem cell applications at BHI Jamaica.

Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is also spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University). Dr. Mehling is also a member of the prestigious International Society for Stem Cell Research (ISSCR).

Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences.
Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke.

For more information, please visit www.bhisciences.com.

Stem Cells Quality Reports

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety.

The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results.

The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke.

For more information, please visit www.bhisciences.com.

BRIAN MEHLING, MD RECEIVES 2020 BEST OF WEST ISLIP AWARD

Brian Mehling, MD, an orthopedic trauma surgeon, has been selected for the 2020 Best of West Islip Award in the Physicians & Surgeons category by the West Islip Award Program.

Each year, the West Islip Award Program identifies companies and individuals that have achieved exceptional marketing success in their local community and business category. They enhance the positive image of small business through service to their customers and the community. As a result, the recipients help make the West Islip area a great place to live, work, and play.

Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is also spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells. 

Various sources of information were gathered and analyzed to choose the winners in each category. The 2020 West Islip Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the West Islip Award Program and data provided by third parties.

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.

“While I appreciate being recognized with this award, it is more of an honor to know that we are providing the highest quality care to our patients” said Dr. Mehling.


Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University). Dr. Mehling is also a member of the prestigious International Society for Stem Cell Research (ISSCR).

Mehling Orthopedics is an orthopedic trauma practice dedicated to creating individualized treatment plans for traumatic injuries and disabilities. With convenient locations in Hackensack, New Jersey, and West Islip, New York, Mehling Orthopedics provides specialized care for orthopedic trauma and sports-related injuries.

The experienced board-certified orthopedic surgeons at Mehling Orthopedics understand that patients need individualized treatment and follow-up care from only the finest medical professionals available. That’s why the team has hired fellowship-trained experts with experience in the latest advances in biomedical processes, autologous stem cell treatments, arthroscopic, and minimally invasive techniques. The team’s physician assistants are specialized in orthopedic trauma and sports medicine.

At Mehling Orthopedics, patient satisfaction is a top priority. With highly-skilled, compassionate physicians, state-of-the-art medical equipment, and the most advanced orthopedic treatment options available, the team makes each one of their patients feel like a member of the family.

In addition to the practice, the Mehling Orthopedics team holds surgical privileges at Hackensack Meridian Health, Hackensack Meridian Health Palisades Medical Center, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hudson Regional Hospital, St. Joseph’s Regional Medical Center, and Mount Sinai St. Luke’s and Mount Sinai West.

Brian Mehling, MD, and Pavel Yufit, MD, are also board-certified by the American Board of Orthopedic Surgeons and members of the American Association of Orthopedic Surgeons. To learn more about the services available at Mehling Orthopedics, visit www.mehlingorthopedics.com

About West Islip Award Program

The West Islip Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the West Islip area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The West Islip Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.

 BHI THERAPEUTIC SCIENCES SCIENTIFIC ADVISORY BOARD CHAIRMAN RECEIVES APPROVAL TO USE STEM CELL PRODUCT IN CLINICAL TRIALS

A Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) product, developed by Wuhan Hamilton Biotechnology Co., Ltd., recently passed inspection by the China National Institute for Food and Drug Control. As a result, the UC-MSCs are a qualified product for application in clinical trials.

Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences. 

“Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses,” said Dr. Wu. “Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases,” he added.

The study will be conducted at Union Hospital, Tongji Medical College Huazhing University of Science and Technology. This study is the first clinical research project registered in Hubei Province with the China Medical Biotechnology Association.

Brian Mehling, MD, founder and chief medical officer of the BHI Therapeutic Sciences and long-time scientific partner with Dr. Wu, said “Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function.”

“Together with Dr. Wu, we are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. 

Dr. Mehling is a practicing American orthopedic trauma surgeon, researcher, and member of the prestigious International Society for Stem Cell Research. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.  Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

Stem cells could be the medical innovation of the century

This article is part of the World Economic Forum Annual Meeting (Davos-Klosters, Switzerland 21—24 January 2020)

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimer’s disease and diabetes). Regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

The current market for stem cell therapies is growing at 36% per year and will rapidly expand when a breakthrough treatment for non-communicable disease or a lifestyle factor occurs. With greater resources and an increasingly experienced talent pool, scientists and physicians may be able to develop stem cell science to cure the world’s most challenging diseases.

For more information please visit https://www.weforum.org/agenda/2020/01/how-will-stem-cells-impact-the-future-of-medicine/

The US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder, Chief Medical Officer, and his team attended the 2020 World Economic Forum in Davos. BHITS is developing a stem cell technology to support regenerative repair with the intent of avoiding surgery as a final option. BHITS believes stem cells possess the potential to treat various diseases, to extend lifespans and to improve the quality of life for certain patients. 

For more information please visitwww.bhisciences.com

BRIAN MEHLING, MD TO PRESENT SPINAL CORD STEM CELL RESEARCH AT ANNUAL MEETING OF THE SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

Brian Mehling, MD has been invited to present his research at the 17th Annual World Congress of the Society for Brain Mapping and Therapeutics being held at the JW Marriott, in Los Angeles, California from Friday March 20-Sunday March 22.

The conference will bring together physicians, scientists, policy makers, funding agencies and industry to further the advances and applications in brain and spinal cord mapping and image guided therapies (operative and non-operative).

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.
His presentation is entitled Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury and the objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. “Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group,” Dr. Mehling said.

“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added.

Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.
The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medical device to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.
This society promotes public welfare and improves patient care through the translation of new technologies/therapies into lifesaving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and industry as well as philanthropic organization.

 WORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 50TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS

The 2020 World Economic Forum (WEF) in Davos will explore the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology.
The US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, MSc, President of BHI Slovakia ; Alan Pereira, President of BHI Brazil ; Marko Cuka, CTO; and Melieck Robinson, International Consultant; is set to attend the annual meeting and participate in conversations, networking events, and attend sessions and panel discussions. This is the eight year, the organization will send representatives to the meeting.
Dr. Mehling explained what stem cells could mean to global health, and how it is creating a future in which many chronic conditions and diseases will be managed with stem cells rather than allopathic medicine or traditional medicine.
“Stem cell treatments are, without a doubt, the future of medicine.” Dr. Mehling states. “It is very important that people making decision on what direction the world will take in regards to research and medical treatments, are educated about not only the possibilities in stem cell research but also about all the treatments that are already available for many patients with different chronic conditions, ” he added.
“By strategically placing our clinic in Slovakia, the heart of Europe, the most innovative research and treatments within the stem cell field is available for the global markets, just 45 minutes away from Vienna International airport, “ said Ms. Novakova.
For more information please visit www.bhisciences.com

BRIAN MEHLING, MD AND BHI THERAPEUTIC SCIENCES TO PRESENT RESEARCH AT AAOS ANNUAL MEETING

Orthopedic surgeon Brian Mehling, MD and his research team at BHI Therapeutic Sciences will exhibit at the American Academy of Orthopedic Surgeons 2020 Annual Meeting, March 24 – 28, at the Orange County Convention Center in Orlando, Florida.
The team will present the results of their study entitled “Adipose Tissue-Derived Stromal Vascular Fraction Cells Application in Subjects with Osteoarthritis and Rheumatoid Arthritis: Retrospective Chart Review Study.” Their results will be presented at booth #1004 located in the West Concourse of the convention center.
“Musculoskeletal disorders are one of the most common reasons that patients seek medical care. The most common musculoskeletal problems are osteoarthritis and rheumatoid arthritis, said Dr. Mehling. “Adipose tissue-derived Stromal Vascular Fraction (SVF) cell therapy is a promising therapeutic option for rheumatoid arthritis and osteoarthritis,” he added.
Dr. Mehling and his team conducted the current retrospective chart review study to analyze the therapeutic efficacy of SVF cells administration in 350 subjects with rheumatoid arthritis and osteoarthritis. In the period from 2015 to 2018, 350 subjects received an intra- articular injection of autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia). The hospital is fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Bratislava, Slovakia. The study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2017- 137).
“Charts were reviewed, and information from subjects’ pain and mobility assessment scales, conducted seven days, three, six and 12 months after therapy, was collected in the data collection forms,” said Marina Manvelyan, Ph.D., clinical research scientist, BHI Therapeutic Sciences.
Assessment of pain and mobility was conducted seven days, three, six and 12 months after SVF cell therapy. Significant decrease in subjects’ pain levels and improvement in mobility were observed three, six and 12 months compared to seven days after therapy. The therapy demonstrated a strong safety profile with no severe adverse events or complications reported.
Dr. Mehling is a practicing American orthopedic trauma surgeon and researcher. He is spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.

Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).

Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.
Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned Annual Meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials.

Blue Horizon International Ambassador Lance Palmer becomes PFL’s first multi-millionaire

On December 31, 2019, Lance Palmer celebrated the new year by defeating Alex Gilpin in a unanimous decision win at Madison Square Garden. The victory gave Palmer the featherweight title for the second year in a row, and another million dollars.
Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training. Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic. “My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and increase in overall energy. I’ve gotten better in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.” BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety.We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board-certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders,autoimmune diseases, and orthopedics conditions. For more information please visit www.bhisciences.com

Blue Horizon International exhibits at World Congress on Anti-Aging Medicine in Las Vegas

Blue Horizon International (BHI), Alpha Blu Skin Care, BHI Therapeutic Sciences, and BHI Rejuve participated in the 27th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2019.
Brian Mehling, M.D. , Founder and Chief Medical Officer of BHI was joined by Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; Alan DaSilvaPereira, President of BHI Brazil; Fidel Desmar, Clinical Research Coordinator; Ralph Moffetone and John-David Grayson from Industrial Motion Pictures.
BHI Therapeutic Sciences (BHITS) is led by an accomplished scientific and medical team and draws on its relationship with international partners who have successfully treated thousands of patients with stem cell therapy.
BHITS was formed to perform research regarding, and to monetize, stem cell technology and associated regenerative medicine. Stem cells are a special type of human cell that can be used to regenerate the human body, in some cases, without drugs or surgery. Regenerative medicine professionals will soon seek to use stem cells to treat various diseases, to extend lifespans and improve the quality of life for certain patients
BHI Rejuve program focuses on anti-aging of the human body, with the help of a complex of vitamins, hormones and stem cell therapy. But the anti-aging part of BHI activities is only one component. Its program is more complex and offers advanced stem cell therapy to patients worldwide.

Blue Horizon International Ambassador Lance “the Party” Palmer is ready to party on New Year’s Eve in Madison Square Garden in NYC

Lance Palmer will be facing Alex Gilpin on December 31, 2019 at the Madison Square Garden in New York City. The fight will air at 7 p.m. EST on ESPN 2.

Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training.

 

Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic. “My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and increase in overall energy. I’ve gotten better in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.”

 

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety. We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board-certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedic conditions.

Check us out before the next decade! Check us out today! 

www.bluehorizoninternational.com

Come party with The Party as he squares off against  Alex Giplin at the Garden tonight! Airs at 7 pm at ESPN 2.

Blue Horizon International CEO Recognized by the International Nurses Association

Doreen Santora, RN, MPH, chief executive officer of Blue Horizon International, will be recognized as a top nurse by the International Nurses Association and will be featured in the publication Worldwide Leaders in Healthcare.

Ms. Santora is receiving this honor for her outstanding acheivements, commitment to education, and demonstrated leadership in her field.

“I am grateful to be recognized by the International Nurses Association,” said Ms. Santora. “It is always nice to be recognized, but when you are honored by your colleagues it is even more special,” she added.

Ms. Santora oversees the operations of Blue Horizon International (BHI) and all of its entities including BHI Therapeutic Sciences, Blue HorizonCharitable Foundation, BHI Rejuve, and Alpha Blu, an innovative skin care line.

She has nearly 30 years of healthcare management experience, Ms. Santora is a registered nurse with a master’s degree in health administration. She is responsible for the day-to-day operations of the BHI and all its subsidies and places a strong emphasis on quality assurance. Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment.
Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center.

She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions including: outpatient surgery, cardiac surgery, cardiology serves, radiology, sleep medicine, women’s health, executive health, plastic and reconstructive surgery, dermatology, medical spa, pain and palliative care, transfusion-free bloodless medicine, heart failure, and home-based healthcare. Ms. Santora was responsible for more than 1,900 employees and an annual budget of $268 million.

BHI Therapeutic Sciences/ Blue Horizon Stem Cells are the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 3,000 stem cell research procedures to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.

The International Nurses Association was founded on the idea that professional achievement is deserving of recognition, exposure and reward. INA is the fastest growing network of nurses from around the globe and takes pride in delivering its members the platform and competitive edge needed to survive in this ever-changing and complex environment. They publish the Nurse Advisor Magazine, Nurse2Nurse Newsletter and others that are packed with the latest advice on stress management, sleep improvement, professional organization and salary negotiating. www.inanurse.com also has blogs, articles and links to helpful resources that can improve quality of life at the clinic or at home. These articles are submitted by nurses, physicians and leading lifestyle experts.

IFBB Pro Champion Anton Antipov Hosts Podcast with Dr. Brian Mehling

On August 2nd, 2019 IFBB Pro Champion and professional fitness model Anton Antipov hosts the podcast Gee Talks, and recently had Dr. Brian Mehling on as a guest to have a long, wide-ranging discussion about the potential of stem cell science.  

Antipov has received three stem cell treatments from Dr. Mehling, once in the BHI clinic in Bratislava, Slovakia, and twice in the new Montego Bay, Jamaica clinic, and intends to receive more.

Click the link below to view the podcast:

Anton Antipov GEE Talks podcast with Dr. Brian Mehling

Living Cells

Live stems cells and primary cells. these images are slices from a 3D hologram made by recording cell density and there is no labelling from LivingCells

Click to view post above

BHI Ambassador and PFL Featherweight Champion Lance Palmer endorses stem cell therapy in BHI Jamaica

Lance Palmer is a featherweight MMA champion who credits stem cell treatments from BHI with a greater feeling of better overall health, more energy, and help with the training recovery process.

Mr. Palmer is a former amateur wrestler and current mixed martial arts fighter. He competes for the Professional Fighters League in the Featherweight division.  A four-time NCAA All-American, Mr. Palmer was a member of the Ohio State wrestling team.

Mr. Palmer recently won a fight on July 25, 2019 at the  Ocean Casino Resort in Atlantic City, New Jersey via unanimous decision, collecting three regular season points. In the second round Palmer faced Luis Rafael Laurentino at PFL 5. He won the fight via third-round TKO and advanced to the playoffs.

Mr. Palmer has said that his successful treatment at the BHI Jamaica, Montego Bay clinic has helped him become a better fighter. He received his first treatment in 2016 and says it helps with the recovery process, preventing injury, and gave him an overall increase in energy.  Mr. Palmer recommends stem cell treatments in general and Dr. Brian Mehling in particular to all other athletes. He describes his experience in the video above.

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading institutions, scientists, and physicians across the globe. We only utilize stem cells from either your own body (autologous) or from umbilical cord donors who have proceeded through a multiple step testing process that ensures stem cell patient safety. We do not use embryonic stem cells, nor will we ever.

BHI Therapeutics Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety. BHI Therapeutics Jamaica provides therapies for neurological disorders, autoimmune diseases, and orthopedics conditions.

Click here to view our testimonial on Lance Palmer

BHl Rejuve attends The Europa Games Nutrition & Wellness Expo

BHI Rejuve, a hormone optimization program, exhibited at the Europa Games Nutrition & Wellness Expo in Dallas on June 8-9, 2019. Attendees of the conference include individuals who are eager to learn more about improving their quality of life. More than 8,000 wellness enthusiast and professional bodybuilders, competing for their “International Federation of Body Builders (IFBB)” professional cards, attended the two-day event.

Representatives from BHI Rejuve presented information on its hormone optimization program and provided awareness regarding the importance of one’s hormone levels and their effect on one’s quality of life.

The Europa Games Expo has been in existence for more than 10 years with several affiliate conferences held throughout the USA. The conferences attract more than 180,000 people annually. It is one of the very few nutrition and wellness conferences that offers the opportunity to obtain IFBB Pro Cards.  In order to become an IFBB pro, a bodybuilder must first earn an IFBB Pro Card. To accomplish this, a bodybuilder l must win a special showcase where he/she is judged on his/her physique.

This year’s conference brought in more than 300 exhibitors, including BHI Rejuve, 24-hour fitness, Bang Energy, Vitamin Shoppe, Orange Theory, US Army, Hello Fresh, Gold’s Gym, and Spartan. Exhibitors had the opportunity to present their companies, goods, and services to bodybuilders, nutrition fanatics and health enthusiasts from across the country.

To check out our video from the event, click the link below.

BHI Rejuve at Europa Games Conference in Dallas

Dr. Brian Mehling presents in Monaco

Brian Mehling, MD, and Michael Kelly, MD had a successful presentation at the Princess Grace Hospital Monaco in Monte Carlo, France.

Dr. Brian Mehling’s presentation was focused on BHI Therapeutic Sciences (BHITS) stem cell research studies.

It included BHITS stem cell therapy methods, results of Institutional Review Board approved stem cell research studies, resent advances in BHITS stem cell research (Presentation at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018 and Presentation at the conference Adult Stem Cells and Regenerative Medicine. The New York Academy of Sciences, NY, 2019) and information on FDA endorsed Investigational New Drug (IND) application entitled Evaluation of the Safety and Efficacy of HPC, Cord Blood in Subjects With Acute Ischemic Stroke.

Dr. Michael Kelly’s presentation was specifically focused on BHITS follow-on IND application entitled “Evaluation of the Safety and Efficacy of Hematopoietic Progenitor Cells, Cord Blood in Subjects with Knee Osteoarthritis Associated Pain”.

It described the study objectives, inclusion and exclusion criteria, safety and efficacy endpoints.

BHI Therapeutic Sciences at World Bank and International Monetary Fund Annual Meetings in DC

Blue Horizon Charitable Foundation was represented at the World Bank and International Monetary Fund Annual Meetings in DC.

This year’s events took place in Washington, D.C. from October 14-20, 2019.
Katarina Novakova, Director of Relations at Blue Horizon Charitable Foundation attended the meetings on behalf of the organization.

The World Bank Group is one of the world’s largest sources of funding and knowledge for developing countries. Its five institutions share a commitment to reducing poverty, increasing shared prosperity, and promoting sustainable development. 

Ms. Novakova said: “Participants were discussing the solutions that can trigger inclusive economic growth, why debt transparency is important, what the workable solutions are to tackle the biodiversity crisis, and what are the actions needed to address the education challenge, especially the number of children who can’t read by the age of ten.”

The program of events showcased unique stories that could help inspire others, such as innovations in creating financial and market opportunities for women entrepreneurs, and how investment and innovation in infrastructure have helped deliver sustainable growth and social development for communities and countries.

To boost action and accelerate progress towards tackling development challenges and reducing extreme poverty, delegates from the member countries, observer organizations, civil society, private sector, and media convened at the 2019 Annual Meetings of the World Bank Group and the International Monetary Fund (IMF).

BHI Therapeutic Sciences studies are registered at the clinical trial registries

Clinical trials are research investigations that play an important role in the development of health information and research for public health care. Clinical trials guiding principles are based on maximum benefit and minimal risk to the participants enrolled in a study.

According to the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association Declaration of Helsinki), “every clinical trial must be registered in a publicly accessible database before recruitment of first subject”. The main registry purpose is to fulfill ethical obligations to participants and the research community and provide information to potential participants and referring clinicians.

BHI Therapeutic Sciences (BHITS) announced the registration of the clinical trial entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” at the ClinicalTrials.gov registry of clinical trials. Initiation of the clinical study, presented in the Investigator-led IND (Investigational New Drug) application, was endorsed by The Food and Drug Administration (FDA). This is a phase one study investigating the safety and efficacy profile of allogeneic cord blood hematopoietic progenitor cells (HPC, Cord Blood), when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke within the past nine days.

To follow the ethical guidelines in clinical research, BHITS retrospectively registered another clinical study entitled “Retrospective chart review study of umbilical cord stem cell therapy for stroke” at the International Standard Randomised Controlled Trials Number (ISRCTN) registry (Biomed Central, Part of Springer Nature). This retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.

“Our research is becoming stronger and we are gaining momentum. It is important to show the scientific community and also the general public the promising results of our research. We are strong believers in stem cell therapies, and are working tirelessly on making it available for a wider audience”, said Brian Mehling, MD, CMO of BHITS, and the Principal Investigator of above mentioned clinical trials.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.    Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders, and other medical conditions.  Multiple studies of umbilical cord blood-derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide range of medical conditions and show promising results. For more information, please visit www.bhisciences.com.

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health and is the largest clinical trials database, currently holding registrations from over 230,000 trials from 195 countries in the world. The National Library of Medicine in the National Institutes of Health made ClinicalTrials.gov available to the public via the internet on February 29, 2000.[6] In this initial release, ClinicalTrials.gov primarily included information about NIH-sponsored trials, omitting the majority of clinical trials being performed by private industry. For more information, please visit www.ClinicalTrials.gov.

The ISRCTN registry is a primary clinical trial registry recognized by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable. ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base. For more information, please visit www.isrctn.com.

BHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE

BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin.

Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues are focusing on in stem cell and regenerative therapies.”

The German Stem Cell Network (GSCN) aims to foster basic and applied stem cell research in Germany. The conference will cover the latest findings in stem cell biology in Germany and includes these scientific sessions:
• Pluripotency and reprograming
• Somatic stem cells and development
• Hematopoietic stem cells
• Stem cells in diseases: cancer stem cells
• Stem cells in regenerative therapies
• Stem cells in disease modeling and drug development
• Computational stem cell biology

“Stem cell therapies are, without a doubt, the future of medicine. I believe

they will become the preferred substitutes for many surgical,

pharmacological, and rehabilitative medical services,”

“The importance of clinical trials and the key direction that it will take will truly

shape the way patients with chronic conditions, disorders, and acute diseases

are treated,” shared Brian Mehling, MD, Chief Medical Officer of BHITS.

BHITS abstract is focused on stroke. Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. To date, there are no clinically effective pharmacotherapies that can promote or facilitate cellular functional recovery after an ischemic stroke. Human umbilical cord blood cell therapy is a promising treatment for ischemic stroke. The current retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.”

Ninety-seven subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in the Wuhan Hongqiao Brain Hospital Co., Ltd. (Wuhan, Hubei) between March 2009 and March 2012, were included in the retrospective chart review study. Subjects received three administrations of 5 ml human umbilical cord blood mononuclear cells (3×10^8) isolated from human umbilical cord blood of three different donors. Treatment was conducted in three sessions via intravenous and intrathecal administrations. This retrospective chart review study was approved by an Institute of Regenerative and Cellular Medicine Institutional Review Board (IRCM approval number: IRCM-2017-135). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).

Analysis of post-stroke physical conditions before and two months after the last human umbilical cord blood mononuclear cell therapy session showed improvement of upper and lower extremity mobility and muscle strength, and neurological function (ability to speak, urinary and bowel function). Significant improvement of upper and lower extremity muscle strength was observed in subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in two or three intrathecal administrations.

 BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.

Brian Mehling, M.D. attends World Economic Forum in Davos

Jan. 30, 2019 – ZURICH, Switzerland — World-renowned stem cell researcher and founder of Blue Horizon International (BHI) and BHI Therapeutic Sciences, Inc. (BHITS) Brian Mehling, M.D. attended the World Economic Forum in Davos to discuss his cellular and regenerative medicine studies and research at the Jan. 22-25 annual meeting in Davos-Klosters, Switzerland.

More than 40 heads of state and government, as well as 3,000 participants drawn from all over the world and from every sphere of influence: business, government, civil society, academia, arts and culture, and media convened at the 49th annual meeting.

“BHI Therapeutic Sciences, Inc. (BHITS) conducts research to support commercialization of stem cell technology to support regenerative medicine.  Stem cells are a multipotent human cell that have the potential to support regenerative repair of the human body. BHITS is developing a stem cell technology to support regenerative repair with the intent of avoiding surgery as a final option,” said Dr. Mehling.

“BHITS believes stem cells possess the potential to treat various diseases, to extend lifespans and to improve the quality of life for certain patients,” he added.

Dr. Mehling was joined by Klara Doert, General Manager of International Business Development, Katarina Novakova, MSc.,  President of BHI Slovakia and Alan Da Silva Pereira, President of BHI Brasil.

Ms. Novakova was nominated for the WEF Young Global Leader, Class of 2019.  Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, created the Forum of Young Global Leaders in 2004 as a way to help the world meet increasingly complex and interdependent challenges, as a community of enterprising, socially minded leaders working as a force for good.

After WEF, Dr. Mehling travelled to Slovakia to visit the BHI Slovakia treatment and research facility in Malacky, approximately 1,5 hour drive from the Vienna International airport.

By strategically placing their clinic in Slovakia, located in the heart of Europe, the most innovative treatments within the stem cell field are available for the global market.

Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts.  

BHI Therapeutic Sciences, Inc. (BHITS) conducts research to support commercialization of stem cell technology to support regenerative medicine.  BHITS is developing a stem cell technology to support regenerative repair with the intent of avoiding surgery as a final option. BHITS believes stem cells possess the potential to treat various diseases, to extend lifespans and to improve the quality of life for certain patients. 

For more information please visit Blue Horizon International at www.bluehorizoninternational.com.

Media contact: knovakova@bluehorizoninternational.com

BHI Therapeutic Sciences exhibits at World Congress on Anti-Aging Medicine in Las Vegas

BHI Therapeutic Sciences (BHITS), BHI Rejuve, and Alpha Blu Skin Care participated in the 26th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2018.

Prominent, influential, and notable leaders in healthcare delivered keynote presentations at the 26th Annual World Congress: all of which were focused on the critical need for both innovation and transformation in medicine. The speakers represented the continual effort to redefine and reshape medicine, and inspired attendees to commit and contribute toward a new century of wellness and longevity.

Brian Mehling, M.D., chief medical officer of BHITS was joined by Klara Doert of BHI Germany; Alan Pereira of BHI Brazil; Fidel Desmar, Brandon Pope, and Katarina Novakova of BHITS, USA.

“Blue Horizon Rejuve program is the latest initiative of BHITS. It focuses on rejuvenation and anti-aging of the human body, with the help of a complex of vitamins, hormones and stem cell therapy,” said Dr. Mehling. “The anti-aging part of BHITS activities is only one component. Its program is more complex and offers advanced stem cell therapy to patients worldwide,” he added.

Blue Horizon International Therapeutic Sciences (BHITS) is a healthcare management company with a unique hospital concept that focuses on providing the highest quality care and service available in surgical and medical treatments, as well as utilizing the most advanced technologies currently available in areas such as stem cell research, operating room technology, hospital management, electronic medical records and medical staff training. BHITS bring the finest doctors and surgeons, medical technology, and hospital management from the United States to the rest of the world with the highest level of care. BHITS is the established brand for the international delivery of the highest quality health care available and staffs medical facilities through the extensive network connections of our Board of Directors, Management Team, Advisory Board Members, and growing international affiliations.  BHITS has established working relationships with some of the most prominent and highly ranked hospitals in the United States and around the world, such as BHI Slovakia and BHI Jamaica. This collaborative work allows for rapid development of research protocols, with the aim of eventually developing less expensive treatments for many of today’s illnesses. Accordingly,  BHITS recruits the very best clinicians from around the world. For more information please visit www.bhsciences.com

BHITS also maintains a special emphasis on charitable work, giving back to the local communities. For more information on our charitable work, please  visit www.bluehorizonfoundation.org. 

 The American Academy of Anti-Aging Medicine, Inc. (“A4M”) is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on anti-aging issues.  The disabilities caused by the human aging process are caused by physiological dysfunctions which in most cases are ameliorable to medical treatment, such that the human life span can be increased, and the quality of one’s life improved as one grows chronologically older. A4M intends to spread awareness about innovative science and research, as well as treatment modalities designed to prolong the human life span. The core of anti-aging medicine is based on scientific principles of comprehensive medical care encompassing those of many other specialties within healthcare.

What do Athletes Need to Know about Stem Cell Therapies?

·        Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain and disability in adult individuals. Systemic inflammation observed in OA is partially reflective of local synovial inflammation. Common treatments for OA include agents for control of pain and inflammation, such as non-steroidal anti-inflammatory drugs, analgesics including opioids, locally administered corticosteroids and viscosupplementation.

·        Cellular therapy is an emerging modality for the treatment of OA. Administration of stem cells with anti-inflammatory function may be effective at preventing or delaying OA if delivered at early stages in the disease process. Human umbilical cord stem cell therapy is safe and effective for articular cartilage regeneration in patients with osteoarthritic knees.

·        BHI Therapeutic Sciences is planning to submit an Investigator-led, research only Investigational New Drug (IND) application for the use of FDA-approved cell therapy (Hematopoietic Progenitor Cells (HPC), cord blood) in the treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HPC, cord blood, when administered by intra-articular injection and intravenous infusion, in subjects with OA.

·        The application of stem cell therapy in the sports medicine arena has expanded in recent years. Orthobiologics are biological substances that orthopaedic surgeons use to help musculoskeletal injuries heal quicker. More information regarding advantages of Orthobiologiscs in sport regenerative medicine can be found in the article “Orthobiologics: What do Athletes Need to Know about Stem Cell Therapies?”

What do Athletes Need to Know about Stem Cell Therapies?

BHI Therapeutic Sciences Inc. Notified by FDA that it can proceed with New Drug Clinical Trial for Acute Ischemic Stroke

BHI Therapeutic Sciences (BHITS), a leader in stem cell therapy and research utilizing human umbilical cord blood, announced today that the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application to allow for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed.

Phase 1/2 Study entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” is a prospective, open-label, single-center, exploratory clinical study that is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in 10 subjects who have sustained an acute ischemic stroke. 

“Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. To date, there are no clinically effective pharmacotherapies that can promote cellular functional recovery after an ischemic stroke. Human umbilical cord blood cell therapy is a promising treatment for ischemic stroke,” said Brian Mehling, M.D., chief medical officer of BHITS. “Stem cell therapy is an exciting, innovative method for the management and treatment of multiple medical conditions. We offer a unique concept that combines treatment and research,” he added.

BHITS will support other follow-on indications using umbilical cord derived stem cells for treatment of traumatic brain injury, including chronic traumatic encephalopathy.  Chronic Traumatic Encephalopathy is a neurodegenerative disease that is found in people with multiple head injuries. It afflicts players in the National Football League. NFL players have committed suicide as a result of the disease. The NFL has set aside nearly $800 million to treat it, but there is currently no treatment. BHITS will also be approaching the NHL and their player’s union. BHITS intends to develop human umbilical cord-derived mesenchymal stem cell product based therapies for use in IND Phase 1 clinical trials in order to extend lifespans and improve the quality of life for patients.

In collaboration with local partners in Slovakia and China, BHITS’ sister company, Blue Horizon International has conducted several clinical investigations. Research subjects with chronic inflammation, musculoskeletal conditions, stroke and spinal cord injury were enrolled in our research studies and successfully treated with the application of human umbilical cord blood cells. In Slovakia, we are working on new clinical protocols (Parkinson’s disease, retinal and optic nerve diseases etc.) and planning to enroll research subjects in our existing and new research studies.

Dr. Mehling’s research has been published in both national and international scientific journals including International Journal of Medical, Health, Biomedical, Bioengineering, and Pharmaceutical Engineering and Stem Cell Research and Therapy.

August 2, 2018      BHI Sciences

BHI Therapeutic Sciences attended the World Economic Forum in Davos, Switzerland.

The 2018 World Economic Forum (WEF) in Davos explored the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology.

During the past few days, the US-based company BHI Therapeutic Sciences (BHITS)
represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert,
President of International Business Development; Katarina Novakova, Director of
Relations; and Manuel McDonald, International Consultant attended the annual meeting and participated in conversations, networking events, and attended sessions and panel discussions. This is the sixth year, the organization sent representatives to the meeting.

Dr. Mehling and his team have met with H.R.H. Crown Prince Haakon of Norway,
Founder of Global Dignity; H.R.H. Crown Princess Mette-Marit; Kofi Annan, former Secretary-General of the United Nations and co-recipient of the 2001 Nobel Peace Prize; Malcolm Stevenson “Steve” Forbes Jr., Editor-in- Chief of Forbes Media; Moira Forbes, EVP at Forbes Media/ Publisher, Forbes Woman; singer, songwriter, dancer and actor Usher; and many CEO’s, Fortune 500 companies C-level executives and government representatives.

BHITS has a treatment and research facility in Bratislava, Slovakia, as well as clinic
facilities in Wuhan, China and Jamaica. The medical team has already successfully
performed 3000 stem cell treatment procedures on more than 1000 patients.
BHITS has conducted several clinical studies testing the safety and efficacy of human umbilical cord blood (hUCB) stem cells. Our clinical studies have provide support for the short and long-term safety of hUCB stem cells for therapy of different medical conditions, including chronic inflammation, musculoskeletal conditions, stroke and spinal cord injury. Our intent is to develop hUCB product based therapies in Investigational New Drug Phase 1 clinical trials in order to extend lifespans and improve the quality of life for patients.

Dr. Mehling explained what stem cells could mean to global health, and how it is creating a future in which many chronic conditions and diseases will be managed with stem cells rather than allopathic medicine or traditional medicine.
“Stem cell treatments are, without a doubt, the future of medicine.” Dr. Mehling states. “It is very important that people making decision on what direction the world will take in regards to research and medical treatments, are educated about not only the possibilities in stem cell research but also about all the treatments that are already available for many patients with different chronic conditions, ” he added.

“By strategically placing our clinic in Slovakia, the heart of Europe, the most innovative research and treatments within the stem cell field is available for the global markets, just 45 minutes away from Vienna International airport, “ said Ms. Novakova.

The theme of this year’s meeting was “Creating a Shared Future in a Fractured World.” It was the first time that the forum's annual meeting featured an all-female panel of co-chairs.
Indian Prime Minister Narendra Modi listed his three most significant challenges to
civilization as we know it: climate change, terrorism and the backlash against
globalization.
Norwegian PM Erna Solberg called for a focus on corruption and illegal money flows and asked for action on gender equality. “Education is the first step”, she said,” making sure that girls take a full part in education.”

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).
Stem cells are a special kind of cell that can be used to regenerate the human body
without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.

August 2, 2018      BHI Sciences

Stem Cells: The Next Frontier documentary screening for investors in NYC.

BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe.

“At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvested from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby),” said Dr. Mehling. “Stem cells are a unique kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain,” he added.

“BHITS has a treatment and research facility in Slovakia, as well as clinic facilities in China and Jamaica. Our medical and scientific teams have published research on the more than 3,000 stem cell treatments have been successfully performed in our clinics,” said Doreen Santora, chief executive officer of BHITS.

Kirk Barton, a retired NFL player, attended the screening. Mr. Barton was a member of the Miami DolphinsSan Francisco 49ersCincinnati Bengals, Denver Broncos and a college standout at Ohio State University, sustaining many injuries during his football career.

It’s a demanding sport. I’ve torn my PCL, MCL, meniscus, shoulder etc. multiple times. I’ve done some research and I decided to try the stem cell therapy offered to me by Dr.Mehling at BHITS in Jamaica. It was like getting a new knee. I never felt better. I recommend it to ton of people because I believe in it,” he said.


His Excellencey Peter Kmec, Ambassador Extraordinary and Plenipotentiary, who served as the Ambassador of Slovakia to the U.S. since September 2012 attended the documentary screening and shared his insight afterwards.

“I was pleased to learn from Katarina Novakova, who spearheaded the BHITS activities in Slovakia, they’ve had more than 250 patients treated in their facility.  I am proud of the company’s innovative approach and wish them success with their future endeavors in Slovakia,” said H.E. Ambassador Kmec.

 

“Innovation is on the top of our current agenda as well. We created a Slovak-American Business and Innovation Council (SABIC) in 2016, through which we would like to channel projects linked to startups, innovation, research, and development and to deepen trade and investment between Slovakia and US. Our goal is to help improve the Slovak innovation ecosystem through bilateral cooperation and to bring Slovakia into the family of the most competitive economies,” he added.

BHITS has conducted several clinical studies testing the safety and efficacy of human umbilical cord blood (hUCB) stem cells. Its clinical studies have provide support for the short and long-term safety of hUCB stem cells for therapy of different medical conditions, including chronic inflammation, musculoskeletal conditions, stroke and spinal cord injury.  Its intent is to develop hUCB product-based therapies in Investigational New Drug Phase 1 clinical trials in order to extend lifespans and improve the quality of life for patients.

BHITS is for looking for accredited investors. The offering can be requested by emailing invest@bhisciences.com.

June 5th, 2018   BHI Sciences